Tag
Genomic testing holds promise for guiding preventive strategies in psychiatry, particularly in high-risk and clinically uncertain contexts; however, current evidence supports targeted rather than universal approaches.
A study reveals a higher prevalence of rapid CYP2C19 metabolizer phenotypes in GERD patients undergoing surgery versus medical therapy, supporting tailored proton pump inhibitor dosing and timely surgical referral.
A randomized clinical trial demonstrates that while CYP2D6 genotyping significantly shifts opioid prescribing patterns for poor and intermediate metabolizers, it does not improve pain control or reduce opioid consumption within the context
In ENLIGHTEN, a biomarker-guided randomized trial, ANK3-positive patients with treatment‑resistant depression randomized to liafensine achieved larger MADRS improvements than placebo (mean difference −4.4; 95% CI −7.6 to −1.3; P = .006), wi
